Dasatinib is a compound developed for chronic myeloid leukemia as a multi-targeted kinase inhibitor against wild-type BCR-ABL and SRC family kinases. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.